ITEM 7.01 REGULATION FD DISCLOSURE
On January 6, 2020, we issued a press release announcing that the U.S. Food and
Drug Administration (FDA) Office of Orphan Products Development has granted
Orphan Drug Designation (ODD) to CLR 131 in Lymphoplasmacytic Lymphoma (LPL). A
copy of the press release is furnished as Exhibit 99.1 and is incorporated by
reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Number Title
99.1 Press release dated January 6, 2020, titled "Cellectar Receives Orphan
Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)"
2
© Edgar Online, source Glimpses